DNA pol λ Inhibitors
DNA pol λ inhibitors encompass a range of compounds that exert their influence indirectly on DNA pol λ, a DNA repair enzyme, by targeting associated cellular processes and pathways. This group of inhibitors does not bind directly to DNA pol λ but affects its activity by modulating the cellular environment and the availability of substrates and cofactors necessary for its function. For example, Aphidicolin and Hydroxyurea operate by substrate competition and depletion, respectively, thereby limiting the resources required by DNA pol λ for DNA synthesis and repair. Etoposide and Camptothecin, through inhibition of topoisomerases, increase the amount of DNA damage, thus potentially overtaxing the repair capacity of DNA pol λ.
DNA pol λ inhibitors introduce DNA lesions that are particularly challenging for repair enzymes, including DNA pol λ, to process, which can indirectly inhibit its activity. Inhibitors disrupt nucleotide pools either through inhibition of synthesis or misincorporation, which can interfere with the base excision repair pathway where DNA pol λ operates. Actinomycin D, by hindering transcription, may affect the expression levels of DNA pol λ or its associated factors. Lastly, NU7441, Mirin, and VE-821 target essential components of DNA damage response pathways, such as DNA-PK, Mre11-Rad50-Nbs1 complex, and ATR kinase, which are upstream of DNA repair processes involving DNA pol λ, thus impacting its role in maintaining genomic stability. These inhibitors underscore the interconnected nature of cellular pathways and highlight the potential for indirect modulation of DNA repair enzymes through strategic targeting of related systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aphidicolin | 38966-21-1 | sc-201535 sc-201535A sc-201535B | 1 mg 5 mg 25 mg | $84.00 $306.00 $1104.00 | 30 | |
A tetracyclic diterpene that selectively inhibits DNA polymerases, especially in the alpha and delta families, and can potentially reduce DNA pol λ activity by competitive inhibition. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
A topoisomerase II inhibitor that can disrupt DNA repair processes, potentially compromising DNA pol λ's role in repairing double-strand breaks. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
A topoisomerase I inhibitor that can lead to DNA damage and interfere with DNA repair pathways, potentially reducing the functional context for DNA pol λ. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
A platinum-based compound that forms DNA crosslinks, potentially hindering DNA synthesis and repair where DNA pol λ is involved. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
An inhibitor of ribonucleotide reductase, reducing deoxyribonucleotide pools and thereby potentially limiting DNA pol λ's substrate availability. | ||||||
β-Lapachone | 4707-32-8 | sc-200875 sc-200875A | 5 mg 25 mg | $112.00 $459.00 | 8 | |
A compound that induces topoisomerase I-mediated DNA damage, potentially increasing the demand on DNA repair mechanisms and overwhelming DNA pol λ's repair capacity. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
An antifolate drug that inhibits dihydrofolate reductase, leading to diminished nucleotide synthesis and potentially affecting DNA pol λ's activity due to substrate depletion. | ||||||
6-Thioguanine | 154-42-7 | sc-205587 sc-205587A | 250 mg 500 mg | $42.00 $54.00 | 3 | |
A guanine analog that gets incorporated into DNA and can disrupt DNA replication and repair, potentially impairing DNA pol λ's function. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
An antibiotic that binds to DNA at the transcription initiation complex and inhibits RNA polymerase, potentially indirectly affecting DNA pol λ by altering transcription of its components. | ||||||
NU 7441 | 503468-95-9 | sc-208107 | 5 mg | $357.00 | 10 | |
A DNA-PK inhibitor that can impair non-homologous end joining, a pathway where DNA pol λ functions, thereby indirectly inhibiting its activity. | ||||||